Drug stability evaluations in elastomeric pump represent the first step to certify the safety of a therapeutic treatment in oncology. Since the stability of several anticancer molecules is due to their reactivity and stability in elastomeric pumps, made up of different materials, several experimental conditions, such as temperature, pH, concentration and possible chemical interactions among drugs in a single formulation, should be always investigated. Galenic preparation of anticancer drugs is an important prerogative of Anticancer Units within hospital pharmacies and, considering the burden of COVID-19 pandemic event, specific guidelines for therapeutic administration in elastomeric pumps reducing hospitalization both for post-surgical treatment and for therapeutic treatment have been worldwide elaborated. In the present study, the stability of Doxorubicin and Vincristine as a single formulation at different experimental conditions has been investigated. Moreover, we report a systematic study of 5-FU, which is known to be largely used in these medical devices, although its criticisms in terms of solubility, pH effect, storage time and conditions. Our results demonstrate that doxorubicin and vincristine can be mixed safely as a single formulation and 5-FU is stable for 32 days at different temperatures and concentrations in elastomeric pumps.
HPLC-UV and LC-MS/MS analysis to study formulation and long-term stability of some anticancer drugs in elastomeric pumps
Nardulli P
;Leopoldo M.;Colabufo, NA
2021-01-01
Abstract
Drug stability evaluations in elastomeric pump represent the first step to certify the safety of a therapeutic treatment in oncology. Since the stability of several anticancer molecules is due to their reactivity and stability in elastomeric pumps, made up of different materials, several experimental conditions, such as temperature, pH, concentration and possible chemical interactions among drugs in a single formulation, should be always investigated. Galenic preparation of anticancer drugs is an important prerogative of Anticancer Units within hospital pharmacies and, considering the burden of COVID-19 pandemic event, specific guidelines for therapeutic administration in elastomeric pumps reducing hospitalization both for post-surgical treatment and for therapeutic treatment have been worldwide elaborated. In the present study, the stability of Doxorubicin and Vincristine as a single formulation at different experimental conditions has been investigated. Moreover, we report a systematic study of 5-FU, which is known to be largely used in these medical devices, although its criticisms in terms of solubility, pH effect, storage time and conditions. Our results demonstrate that doxorubicin and vincristine can be mixed safely as a single formulation and 5-FU is stable for 32 days at different temperatures and concentrations in elastomeric pumps.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.